Long term probability of detecting HIV drug resistance in drug-naïve patients starting non nucleoside reverse transcriptase inhibitor- or ritonavir boosted protease inhibitor- containing antiretroviral therapy. (Record no. 75761)

MARC details
000 -LEADER
fixed length control field 03836cam a2200193 4500
001 - CONTROL NUMBER
control field NMDX6596
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 120401t2010 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 10584838
110 ## - MAIN ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element UK Collaborative Group on HIV Drug Resistance
240 ## - UNIFORM TITLE
Uniform title <a href="Clinical infectious diseases">Clinical infectious diseases</a>
245 ## - TITLE STATEMENT
Title Long term probability of detecting HIV drug resistance in drug-naïve patients starting non nucleoside reverse transcriptase inhibitor- or ritonavir boosted protease inhibitor- containing antiretroviral therapy.
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc. 2010
500 ## - GENERAL NOTE
General note NMUH Staff Publications
500 ## - GENERAL NOTE
General note 50
520 ## - SUMMARY, ETC.
Summary, etc. &lt;br /&gt;&lt;div style="line-height: 17.999801635742188px;"&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;BACKGROUND:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;Robust long-term estimates of the risk of development of drug resistance are needed for human immunodeficiency virus (HIV)-infected patients starting combination antiretroviral therapy (cART) regimens currently used in routine clinical practice.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;METHODS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;We followed a large cohort of patients seen in 1 of 11 HIV clinics in the United Kingdom after starting cART with nucleoside reverse-transcriptase inhibitors and either a nonnucleoside reverse-transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r). Survival analysis was employed to estimate the incidence of virological failure and of detected drug resistance.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;RESULTS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;Seven thousand eight hundred ninety-one patients were included; 6448 (82%) started cART with an NNRTI and 1423 (17%) with a PI/r. The cumulative risk of virological failure by 8 years was 28%. The cumulative probabilities of detecting any mutation, &amp;gt; or =1 major nucleoside reverse-transcriptase inhibitor International AIDS Society-United States of America (IAS-USA) mutation, &amp;gt; or =1 major NNRTI IAS-USA mutation (in those starting an NNRTI), and &amp;gt; or =1 major PI IAS-USA mutation (in those starting a PI) were 17%, 14%, 15%, and 7%, respectively, by 8 years. The probability of detecting PI mutations in people who started PI/r-based regimens was lower than that of detecting NNRTI mutations in those starting NNRTI-based regimens (adjusted relative hazard, 0.36; 95% confidence interval, 0.26-0.50; P&amp;lt;.001). The risk of detecting nucleoside resistance did not vary according to whether an NNRTI or a PI/r was used in the regimen (adjusted relative hazard, 1.00; 95% confidence interval, 0.80-1.26; P=.98).&lt;/span&gt;&lt;/p&gt;&lt;h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"&gt;&lt;span style="font-size: 8pt;"&gt;CONCLUSIONS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em;"&gt;&lt;span style="font-size: 8pt;"&gt;In patients who started modern cART in clinical practice in the United Kingdom, virological failure by 8 years was relatively common and was paralleled by an appreciable risk of resistance detection, although the detection rate of class-specific resistance was lower for those who started a PI/r-based regimen.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;
710 ## - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element UK CHIC Study Group
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://www.ncbi.nlm.nih.gov/pubmed/20353366">http://www.ncbi.nlm.nih.gov/pubmed/20353366</a>
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://cid.oxfordjournals.org/content/50/9/1275.full.pdf+html">http://cid.oxfordjournals.org/content/50/9/1275.full.pdf+html</a>
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection code Home library Current library Shelving location Date acquired Total Checkouts Date last seen Price effective from Koha item type
        Staff publications for NMDX Ferriman information and Library Service (North Middlesex) Ferriman information and Library Service (North Middlesex) Shelves 07/06/2022   07/06/2022 07/06/2022 Book
London Health Libraries Koha Consortium privacy notice